Nemaura Medical, Inc. · OTC:NMRD
Nemaura Medical — Investor Presentation (April 2017)
22 slides from Nemaura Medical's investor presentation, Apr 20, 2017
Slide 1: Nemaura Medical Corporate Presentation April 2017
ee WN) NEMAURA MEDICAL (OTCBB: NMRD) Better Diagnostics for Life Corporate Presentation April 2017
Slide 2: Forward-looking statements
This presentation includes forward-looking statements that are subject to many risks and uncertainties. These forward-looking statements, such as statements about Nemaura’s short-term and long-term growth strategies, can sometimes be identified by use of terms such as “intend,” “expect,” “plan,” “es
Slide 3: Nemaura Medical company overview
Nemaura Medical is a UK-based innovator of unique diagnostic medical devices that have evolved out of our core area of expertise in transdermal drug delivery. We believe empowering patients to easily monitor key analytes via our proprietary BEAT™ technology will result in better management of multip
Slide 4: Market Dynamics
Market Dynamics A large and growing opportunity Global Wearable Technology Market ssa Global Healthcare Device Market sts Global Diabetes Market Adults with Diabetics Worldwide Europe Glucose Monitoring Market U.S. Glucose Monitoring Market $4.8 Bn+ oSelf-monitoring: $4.1B Wcif-mbnitoring: $2.8B ynt
Slide 5: BEAT Platform Summary
BEAT™ Platform Summary Ability to address a wide variety of patient needs Daily-disposable adhesive ‘Band-Aid’ type skin-patch integrated with Bluetooth-enabled sensor connected to pre-downloaded App on users smart device \ Smartwatch Smartphone or Tablet ) NEMAURA
Slide 6: How the BEAT patch extracts glucose
The BEAT™ patch extracts glucose from below the skin to the surface on to a patch containing a sensor. The Bluetooth-enabled sensor measures and transmits glucose data to a proprietary application pre-downloaded on user's own smartwatch / smartphone A proprietary algorithm within the application con
Slide 7: G1 commercial launch and regulatory timeline
SugarBEAT® G1 commercial launch expected Q3 2017 in UK CE Mark granted Q1 2016 on predecessor version (watch format) Bridging CE approval required for wireless version as adjunct device, with CE submission due in Q3 2017 and PMA submission in Q4 2017 Pre-downloaded App on Smartphone, Tablet, Smartwa
Slide 8: SugarBEAT sensor and patch specifications
vApproximate 30 minutes warm-up period vSensor measures glucose within extracted interstitial fluid vSensor records a reading every 5 minutes and transmits via Bluetooth to user’s smart device vEach disposable skin-patch lasts up to 24 hours vFinger prick calibration required whenever new patch is a
Slide 9: Targeted Market Size by Diabetic Population
SugarBEAT® Targeted Market Size 4 by Diabetic Population “> Target reimbursement for Insulin Dependent Adult Diabetics as low-cost adjunct CGM solution “> Target adult cash-payers for type II diabetics ce Total number of Diabetics Type + Insulin dependent Type2 oy (million) Type 2* (million) (millio
Slide 10: Continuous Glucose Monitoring Competitive Landscape
SugarBEAT® Continuous Glucose Monitoring Competitive Landscape FreeStyle Libre™ © Platinum @ GS™ SugarBEAT® G1 ‘Manufacturer Abbott DexCom Senseonics ‘Nemaura Medical Techunlogy Inserted Sensor Inserted Sensor Implanted Seasor mani @ 114% 90% u = [oo Reliability 0 7 C4 (Clarke Error Grid A+B zone) S
Slide 11: SugarBEAT Competitive Advantage Analysis
SugarBEAT™ Continuous Glucose Monitoring Competitive Advantage Analysis For Diabetics Injecting Insulin For Diabetics Not Injecting Insulin _ For All Diabetics (Approx. 15% of diabetic market) (Approx. 85% of diabetic market) Reimbursement market Cash payers market - Core USP - Price Core USP - Non-
Slide 12: G1 Development Milestones
SugarBEAT® Continuous Glucose Monitoring G1 Development Milestones Q32018& thereafter Launch maj Saudi & HK Receive PMA approval ) NEMAURA 12
Slide 13: SugarBEAT Active R&D Pipeline
SugarBEAT™ Active R&D Pipeline Product Key Features Target Market ifestyle ty 5 their glucose trends No finger prick calibration required Include Pediatric Cover SugarBEAT G2 * Increased patch wear time Type I and Type II Diabetics Improved Accuracy (MARD) Provide accurate CGM for immobile patients
Slide 14: BEAT Platform Future R&D Pipeline
BEAT™ Platform Future R&D Pipeline Analyte* Uses Diagnostics Phenylalanine monitoring to ensure that the level is Phenylalanine sufficiently suppressed Phenylketonuria (PKU) Screening for inflammatory irritants in formulations during drug and cosmetic development Prostaglandin Inflammation Lactate L
Slide 15: Clinical Data
SugarBEAT® Clinical Data Evaluation of Clinical Data used for CE Mark granted in Q1 2016 Study Criteria and Performance Metrics The following criteria have been employed to measure the performance of the sugarBEAT® device. Parameter Study 1 Study 2 Reference Device HemoCue Laboratory finger prick gh
Slide 16: Clinical Trials
SugarBEAT® Clinical Trials A © Clinical Data in Type Land II Diabetics 100 patient day: 30 patients, 3 or 4 visits, 12 — 14 hr wear/day — ZERO skin ittitation recorded Recent data indicates MARD of <15% achievable InvasiveCGM ——-Dexcom G4* 4634 10.8% 84.50% 15.10% 0.94 Invasive CGM Medtronic Enlite*
Slide 17: SugarBEAT Clinical Dataset Example
| SugarBEAT® Clinical Dataset Example 1 © Stage 2 Study: Example of CGM sensitivity of non-diabetic within euglycemic range Blood Glucose Concentration (mmol/L) vs. Time (mins) % Glucose Drink Glucose = anaes ss Sm: 1 taken at 80 Drink 2 aca Trey ‘minutes taken at 160 440 Drink Plus = 850 minutes Fr
Slide 18: Clinical Dataset Example
SugarBEAT® Clinical Dataset Example 2 Stage 2 Study: Example 1 of CGM sensitivity in insulin dependent Type 2 Blood Glucose Concentration (mmol/L) vs. Time (mins) Dinner taken at 360 minutes Snack at 600 minutes 35.0 30.0 25.0 20 20mits a Equilbrated Tnsulin at within 1 hour 240 minutes Calibrated B
Slide 19: G1 in-house testing and sensor improvements
SugarBEAT® G1 skin-patch and sensor successfully tested in-house SugarBEAT® G1 App successfully tested in-house (Medical Device Grade) SugarBEAT® G1 sensor performance improved, with almost 2 order of magnitude enhancement to detection limit Additional patent filed in Jan 2017 to cover new sensor fe
Slide 20: Management team
Dr. Dewan Fazlul Hoque Chowdhury Chief Executive Officer Over 18 years' experience in the pharmaceutical and medical device industry and holder of over 50 patents across more than 15 patent families 2009-Present: President, Chief Executive Officer and Board Director in charge of research and develop
Slide 21: Intellectual Property
Intellectual Property EU, USA, JP, CA+ others Patch Construction Pending elsewhere EU, USA, JP, CA + others Pending EU, USA, JP, CA + others Pending
Slide 22: Corporate Structure
lk Corporate Structure ie) s (Holdings) Dermal Diagnostics Ltd. Trial Clinic Ltd. England & Wales)